Marc Beer is a renowned man in the world of diagnostics, pharmaceuticals, and biotechnology with much experience in this field. In the past, he has worked for ViaCell as a CEO, as a member of the board of directors in Pharma (NASDAQ: ERYP), held various positions in Genzyme where he recently worked as a Vice President in Global Marketing. He has held many positions in sales and marketing for Abbott Laboratories (NYSE: ABT) pharmaceutical and diagnostic divisions. He was also a member of the Mass life Science Board of the Commonwealth of Massachusetts and helped in the Biotechnology Industry Organisation (BIO) Emerging Companies Section Governing Board.
Additionally, he was a Founding Chairman of the board of directors and chairman of the compensation committee of Good Start Genetics. He is also a Founding of the board, Chairman of the compensation committee and member of the audit committee of Minerva Neurosciences. He is one of the members Business Advisory Council of Miami University. Marc holds a bachelors degree from Miami University and is a former member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council.
He is the CEO, Chairman, and a Co-founder of Renovia where he has registered significant progress in technology and treatment of various types of pelvic disorders.
One of his greatest achievements is the close of $42M in financing including $10 M in venture debt and $32.3M in Series B that he has raised to continue building Renovia. Learn more: https://ideamensch.com/marc-beer/
The research has already borne some fruits with Renovia’s first product Leva getting approved by the FDA. The funds will help in duplication of Leva, diagnostic equipment, conducting clinical trials and for future commercial launches. In a statement he gave, he said that they were happy to have the support of other healthcare investors. He further added that there were organizations with the same vision as that of Renovia of analyzing and treating with the aim of changing the lives of women who suffer from pelvic disorders. He finally said that with the combination of innovation and technology they would offer relevant information that would give better treatment options, increase knowledge and understanding which would reduce the cost of health care in the long run.